<DOC>
	<DOCNO>NCT00427297</DOCNO>
	<brief_summary>Globally , child acquire HIV-1 increasingly context maternal antiretroviral prophylaxis . It important determine whether maternal antiretroviral prophylaxis alter infant treatment regimen . Nevirapine ( NVP ) commonly use PMTCT also commonly use first-line drug treatment pediatric HIV-1 . Approximately half infant expose NVP detectable NVP resistance early infancy , loss detectable resistance time . Thus , HIV-1 infect child expose single-dose NVP prophylaxis , question remain whether NVP NNRTI use effectively therapeutic regimen . Alternative PI-based regimen associate heat-lability , poor palatability , cumulative toxicity , few salvage option . This pose challenge pediatric PI-based highly active antiretroviral therapy ( HAART ) setting without refrigeration limit antiretroviral repertoire . It plausible old NVP-exposed infant ( old 6 month since exposure ) genotypically NVP-susceptible , nevirapine effective useful . We propose study resistance pediatric HIV-1 clinical trial involve 100 child . Among child enrol 6 18 month age , provide real-time field-based genotypic NVP-resistance testing , randomize 100 NVP-susceptible child NVP-containing versus NVP-sparing HAART compare therapeutic response , adverse event , morbidity 2 arm 2-year follow-up . Follow-up study closely monitor external Data Safety Monitoring Board ( DSMB ) .</brief_summary>
	<brief_title>Optimizing Pediatric HIV-1 Treatment Infants With Prophylactic Exposure Nevirapine , Nairobi , Kenya</brief_title>
	<detailed_description>Hypotheses 1 . Infants older 6 month detectable nevirapine resistance genotypic test respond equivalently nevirapine-sparing nevirapine-containing HAART regimen , despite previous single-dose nevirapine exposure . 2 . Genotypic drug resistance level may predict response therapy clinical progression . Specific Aims/Primary Objectives 1 . To compare response therapy ( viral level , CD4 % , growth , morbidity ) infant without detectable nevirapine-resistance population-based sequence randomize nevirapine-containing versus nevirapine-sparing HAART . 2 . To develop method detect quantify nevirapine resistance mutation present low frequency virus population order examine relationship copy number variant virologic failure infant treat nevirapine-containing HAART . Secondary Aim/Secondary Objective : To determine predictor non-progression study , include : age , time since nevirapine-exposure , adherence , HIV-1 specific immune response , baseline HIV-1 RNA , CD4 percent , immune activation . Design : Randomized clinical trial infant 6-18 month age randomize nevirapine contain versus nevirapine spar HAART regimen follow 24 month . Population : HIV-1 infected infant ( 6-12 month ) meeting eligibility enrol . Infants expose nevirapine in-utero follow delivery , detectable resistance nevirapine eligible enrollment . Sample size : 100 infant enrol ( 50 infant arm ) . Treatment : All infant treat NVP contain spar HAART . The regimen prescribe accord WHO Kenyan national guideline dosage combination antiretroviral drug . The HAART regimen use study : First line regimen : For infant NVP contain HAART - AZT/3TC/NVP ( zidovudine/lamivudine/nevirapine ) - d4T/3TC/NVP ( stavudine/lamivudine/nevirapine ) - ABC/3TC/NVP ( abacavir/lamivudine/nevirapine ) For infant NVP spar HAART - AZT/3TC/ABC ( zidovudine/lamivudine/abacavir ) - d4T/3TC/ABC ( stavudine/lamivudine/abacavir ) For child anaemia ( Hb &lt; 8g/dl ) , AZT substitute d4T . Second line regimen : - ddI/ABC/LPV/r ( didanosine/abacavir/lopinavir-ritonavir ( kaletra ) ) - ABC / ddI TDF / NVP EFV ( abacavir / didanosine tenofovir / nevirapine efavirenz ) Among child randomize NVP spar HAART , initiated regimen contain lopinavir/ritonavir , zidovudine lamivudine substitute abacavir didanosine tenofovir ( TDF ) lopinavir/ ritonavir replace nevirapine efavirenz ( EFV ) case treatment failure LPV/r contain regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>618 month age HIV1 DNA detection confirmation ( positive two HIV1 DNA filter paper test ) Mother expose NVPcontaining PMTCT regimen currently end pregnancy and/or infant receive NVPcontaining PMTCT regimen Infant susceptible NVP ( i.e . detectable NVP resistance genotypic test ) Caregiver infant plan reside Nairobi least 3 year Caregiver able provide sufficient location information Infant receive prior antiretroviral therapy ( expect prophylaxis PMTCT ) Infant evidence active tuberculosis Mother currently receive NVPcontaining HAART breastfeeding infant</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Pediatric</keyword>
	<keyword>nevirapine</keyword>
	<keyword>HAART</keyword>
	<keyword>Resistance</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>